Abstract: Methods and systems for preparing and preserving biological samples are disclosed herein. A method comprises contacting a preserving agent with a biological sample to form a mixture, wherein the preserving agent is selected from at least one of a metal-organic framework (MOF) encapsulant or a precursor forming a MOF encapsulant, and wherein the biological sample comprises at least one target analyte. A system comprises a preserving agent selected from at least one of a metal-organic framework (MOF) encapsulant or a precursor forming a MOF encapsulant; and a substrate configured to receive a drop cast mixture of the preserving agent and a biological sample, wherein the biological sample comprises at least one target analyte.

Abstract: Disclosed herein is a fluorescent nanoconstruct that includes a plasmonic nanostructure having at least one localized surface plasmon resonance wavelength (?LSPR), at least one spacer coating, at least one fluorescent agent having a maximum excitation wavelength (?EX), and wherein the fluorescent nanoconstruct has a fluorescent intensity that is at least 500 times greater than a fluorescent intensity of the at least one fluorescent agent alone.

Abstract: Methods and systems for preparing and preserving biological samples are disclosed herein. A method comprises contacting a preserving agent with a biological sample to form a mixture, wherein the preserving agent is selected from at least one of a metal-organic framework (MOF) encapsulant or a precursor forming a MOF encapsulant, and wherein the biological sample comprises at least one target analyte. A system comprises a preserving agent selected from at least one of a metal-organic framework (MOF) encapsulant or a precursor forming a MOF encapsulant; and a substrate configured to receive a drop cast mixture of the preserving agent and a biological sample, wherein the biological sample comprises at least one target analyte.

Abstract: Disclosed are diagnostic reagents having metal-organic frameworks and protection and enhancement of diagnostic reagents and materials using metal-organic frameworks.

Abstract: Plasmonic nanotransducers, methods of preparing plasmonic nanotransducers, and methods for label-free detection of target molecules are disclosed. The plasmonic nanotransducers include hollow nanostructure cores and artificial antibodies. The plasmonic nanotransducers are exposed to a biological sample that can contain the specific target molecules. The plasmonic nanotransducers can be analyzed with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the target molecule in the sample.

Abstract: Plasmonic nanotransducers and methods for label-free detection of biomarkers are disclosed. The plasmonic nanotransducers include nanostructure cores and peptide aptamers. The plasmonic nanotransducers are exposed to a biological sample that can contain the specific biomarkers and can be analyzed with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the biomarker in the sample.

Abstract: Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with, a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein, and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer.

Abstract: Plasmonic nanotransducers, methods of preparing plasmonic nanotransducers, and methods for label-free detection of target molecules are disclosed. The plasmonic nanotransducers include hollow nanostructure cores and artificial antibodies. The plasmonic nanotransducers are exposed to a biological sample that can contain the specific target molecules. The plasmonic nanotransducers can be analyzed with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the target molecule in the sample.

Abstract: Natural and/or synthetic antibodies for specific proteins are adhered to nanoparticles. The nanoparticles are adhered to a substrate and the substrate is exposed to a sample that may contain the specific proteins. The substrates are then tested with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the specific protein in the sample.

Abstract: Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with, a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein, and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer.

Abstract: Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer.

Abstract: Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer.

Abstract: Monoclonal antibodies specific for an antigen present on the surface of parathyroid tissue are useful in imaging such tissue when conjugated to suitable label. The antibodies of the invention bind exclusively to parathyroid surfaces and do not bind to other tissues. The antibodies are useful in establishing the location of the parathyroid whether in its normal location or in ectopic placements. An exemplary monoclonal has been deposited at the American Type Culture Collection and has accession number ATCC No. HB9917.

Abstract: Monoclonal antibodies specific for an antigen present on the surface of parathyroid tissue are useful in imaging such tissue when conjugated to suitable label. The antibodies of the invention bind exclusively to parathyroid surfaces and do not bind to other tissues. The antibodies are useful in establishing the location of the parathyroid whether in its normal location or in ectopic placements. An exemplary monoclonal has been deposited at the American Type Culture Collection and has accession number ATCC No. HB9917.